[144] Immunocore Holdings plc American SEC Filing

Rhea-AI Filing Summary

Insider notice to sell 135,000 American Depositary Shares (ADS) of Immunocore Holdings plc (IMCR) is reported on Form 144. The shares are to be sold through J.P. Morgan Securities LLC on 09/10/2025 with an aggregate market value of $4,939,650. The filing shows the ADS were acquired and will be sold on 09/10/2025 via a stock option exercise, with payment made in cash. The issuer has 50,387,068 ADS outstanding per the form. The filer reports no other securities sold in the past three months and certifies no undisclosed material adverse information.

Positive

• Full disclosure of proposed sale details including broker, date, share count, and aggregate market value
• Transaction executed through a reputable broker (J.P. Morgan Securities LLC)
• Securities acquired and disposed on same date via stock option exercise with cash payment
• No sales in the past three months reported by the filer

Negative

• None.

Insights

Securities Analyst

TL;DR Routine insider sale following option exercise; represents a small percentage of shares outstanding and is processed through a major broker.

The Form 144 documents a proposed disposition of 135,000 ADS valued at $4.94 million to be executed on 09/10/2025 via J.P. Morgan Securities LLC. The securities were acquired and are being sold on the same date through a stock option exercise, with cash payment noted. There are no reported sales by the filer in the prior three months. For investors, this filing is a disclosure of an insider liquidity event rather than evidence of company operational changes.

Corporate Governance Expert

TL;DR Filing meets Rule 144 disclosure requirements; no additional governance red flags are evident from the notice alone.

The filer represents compliance with Rule 144 and affirms absence of undisclosed material adverse information. The sale is routed through an established broker and the transaction follows a stock option exercise with cash proceeds. The disclosure does not indicate aggregated sales in prior months and contains the standard certification language regarding material information. From a governance perspective, this is a standard insider liquidity disclosure.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	J.P. Morgan Securities LLC 390 Madison Avenue - 6th Floor New York NY 10017	135000	4939650	50387068	09/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	09/10/2025	Stock Option Exercise	Issuer			135000	09/10/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for IMCR report?

The form reports a proposed sale of 135,000 ADS of Immunocore (IMCR) valued at $4,939,650, to be sold on 09/10/2025 through J.P. Morgan Securities LLC.

How were the ADS being sold on the Form 144 acquired?

The ADS were acquired on 09/10/2025 by a stock option exercise and the table lists cash as the nature of payment.

What percentage of outstanding ADS does the sale represent?

The form lists 50,387,068 ADS outstanding; the proposed sale of 135,000 ADS represents a small fraction of that total as reported on the filing.

Did the filer report other sales in the prior three months?

No; the form states "Nothing to Report" for securities sold during the past three months by the filer.

Does the filing indicate any undisclosed material information about the company?

By signing, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.